Form 4: Cytek Biosciences CEO Wenbin Jiang Reports Stock Transactions Following RSU Vesting

Cytek Biosciences CEO Wenbin Jiang acquired shares through the vesting of Restricted Stock Units (RSUs) and subsequently sold some shares to cover tax obligations.

Summary

• Cytek Biosciences CEO Wenbin Jiang reported transactions related to the vesting of Restricted Stock Units (RSUs).
• On November 18, 2024, Mr. Jiang acquired a total of 40,639 shares of common stock through the vesting of RSUs.
• Simultaneously, 9,897 shares were withheld by the company to cover tax obligations at a price of $6.03 per share.
• After these transactions, Mr. Jiang's direct holdings increased to 5,187,638 shares of common stock.
• The RSUs vest over four years, with varying portions vesting quarterly on specific dates.

Sentiment

Score: 7

Explanation: The document reflects routine transactions related to executive compensation, which is neither particularly positive nor negative. The transactions are expected and do not indicate any significant change in the company's outlook.

Industry Context

This is a routine filing related to executive compensation and is common for publicly traded companies. It reflects the standard practice of granting stock-based compensation to executives and the subsequent tax withholding process.

Comparison to Industry Standards

• The vesting schedule of the RSUs is typical for executive compensation packages in the biotech industry, with vesting occurring over a four-year period.
• The practice of withholding shares to cover tax obligations is a standard procedure for RSU vesting.
• Other biotech companies such as Bio-Rad Laboratories and Illumina also use similar stock-based compensation plans for their executives.

Stakeholder Impact

• The transactions have a minor impact on shareholders as they reflect the standard practice of executive compensation.
• The vesting of RSUs is part of the overall compensation package for the CEO.

Key Dates

Keywords

Cytek Biosciences, Wenbin Jiang, Restricted Stock Units, RSU, Stock Vesting, SEC Form 4, Insider Trading, Executive Compensation